{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T22:12:03Z","timestamp":1648678323184},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T00:00:00Z","timestamp":1468368000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00059-016-4457-x","type":"journal-article","created":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T10:30:44Z","timestamp":1468405844000},"page":"413-420","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hypercholesterin\u00e4mie \u2013 Wo stehen wir heute? Wo wollen wir hin?"],"prefix":"10.1007","volume":"41","author":[{"given":"A. K.","family":"Gitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,13]]},"reference":[{"key":"4457_CR1","volume-title":"Gesundheit \u2013 Todesursachen in Deutschland 2014, Fachserie 12 Reihe 4","author":"Statistisches Bundesamt","year":"2016","unstructured":"Statistisches Bundesamt (2016) Gesundheit \u2013 Todesursachen in Deutschland 2014, Fachserie 12 Reihe 4. Statistisches Bundesamt, Wiesbaden"},{"key":"4457_CR2","doi-asserted-by":"crossref","first-page":"888","DOI":"10.7326\/0003-4819-61-5-888","volume":"61","author":"WB Kannel","year":"1964","unstructured":"Kannel WB, Dawber TR, Friedman GD, Glennon WE, McNamara PM (1964) Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease; the Framingham study. Ann Intern Med 61:888\u2013899","journal-title":"Ann Intern Med"},{"key":"4457_CR3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267\u20131278","journal-title":"Lancet"},{"key":"4457_CR4","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670\u20131681","journal-title":"Lancet"},{"key":"4457_CR5","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2008.08.039","volume":"52","author":"EJ Mills","year":"2008","unstructured":"Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D (2008) Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 52:1769\u20131781","journal-title":"J Am Coll Cardiol"},{"key":"4457_CR6","doi-asserted-by":"crossref","first-page":"b2376","DOI":"10.1136\/bmj.b2376","volume":"338","author":"JJ Brugts","year":"2009","unstructured":"Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG et al (2009) The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 338:b2376","journal-title":"BMJ"},{"key":"4457_CR7","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Z Reiner","year":"2011","unstructured":"Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O et\u00a0al (2011) ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32:1769\u20131818","journal-title":"Eur Heart J"},{"key":"4457_CR8","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P et\u00a0al (2015) Ezetimibe added to Statin therapy after acute coronary syndromes. N Engl J Med 372:2387\u20132397","journal-title":"N Engl J Med"},{"key":"4457_CR9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","volume":"67","author":"SA Murphy","year":"2016","unstructured":"Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y et al (2016) Reduction in total cardiovascular events with Ezetimibe\/Simvastatin post-acute coronary syndrome: the IMPROVE-IT trial. J Am Coll Cardiol 67:353\u2013361","journal-title":"J Am Coll Cardiol"},{"key":"4457_CR10","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","volume":"36","author":"T Jernberg","year":"2015","unstructured":"Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M (2015) Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 36:1163\u20131170","journal-title":"Eur Heart J"},{"key":"4457_CR11","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/2047487315569401","volume":"23","author":"K Kotseva","year":"2016","unstructured":"Kotseva K, Wood D, De Bacquer D, De Backer G, Ryden L, Jennings C et\u00a0al (2016) EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 23:636\u2013648","journal-title":"Eur J Prev Cardiol"},{"key":"4457_CR12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1741826711400545","volume":"19","author":"AK Gitt","year":"2012","unstructured":"Gitt AK, Drexel H, Feely J, Ferrieres J, Gonzalez-Juanatey JR, Thomsen KK et al (2012) Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol 19:221\u2013230","journal-title":"Eur J Prev Cardiol"},{"key":"4457_CR13","first-page":"71","volume":"9","author":"JR Schaefer","year":"2013","unstructured":"Schaefer JR, Gitt AK, Sonntag F, Weizel A, Jannowitz C, Karmann B et\u00a0al (2013) Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry. Vasc Health Risk Manag 9:71\u201380","journal-title":"Vasc Health Risk Manag"},{"key":"4457_CR14","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.amjcard.2007.03.102","volume":"100","author":"JC LaRosa","year":"2007","unstructured":"LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H, Treating to New Targets Steering Committee and Investigators (2007) Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol 100:747\u2013752","journal-title":"Am J Cardiol"},{"key":"4457_CR15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","volume":"355","author":"P Amarenco","year":"2006","unstructured":"Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE et al (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355:549\u2013559","journal-title":"N Engl J Med"},{"key":"4457_CR16","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","volume":"294","author":"TR Pedersen","year":"2005","unstructured":"Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I et al (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294:2437\u20132445","journal-title":"JAMA"},{"key":"4457_CR17","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","volume":"57","author":"J Hsia","year":"2011","unstructured":"Hsia J, MacFadyen JG, Monyak J, Ridker PM (2011) Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol\u300850\u202fmg\/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 57:1666\u20131675","journal-title":"J Am Coll Cardiol"},{"key":"4457_CR18","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","volume":"64","author":"SM Boekholdt","year":"2014","unstructured":"Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR et al (2014) Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 64:485\u2013494","journal-title":"J Am Coll Cardiol"},{"key":"4457_CR19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1185\/03007995.2015.1120715","volume":"32","author":"AK Gitt","year":"2016","unstructured":"Gitt AK, Sonntag F, Jannowitz C, Weizel A, Karmann B, Schaefer JR et\u00a0al (2016) Better lipid target achievement for secondary prevention through disease management programs for diabetes mellitus and coronary heart disease in clinical practice in Germany. Curr Med Res Opin 32:417\u2013426","journal-title":"Curr Med Res Opin"},{"key":"4457_CR20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/clc.22241","volume":"37","author":"R Reibis","year":"2014","unstructured":"Reibis R, Voller H, Gitt A, Jannowitz C, Halle M, Pittrow D, Hildemann S (2014) Management of patients with ST-segment elevation or non-ST-segment elevation acute coronary syndromes in cardiac rehabilitation centers. Clin Cardiol 37:213\u2013221","journal-title":"Clin Cardiol"},{"key":"4457_CR21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1185\/03007995.2014.977854","volume":"31","author":"R Reibis","year":"2015","unstructured":"Reibis R, Jannowitz C, Halle M, Pittrow D, Gitt A, V\u00f6ller H (2015) Management and outcomes of patients with reduced ejection fraction after acute myocardial infarction in cardiac rehabilitation centers. Curr Med Res Opin 31:211\u2013219","journal-title":"Curr Med Res Opin"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-016-4457-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-016-4457-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-016-4457-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T18:19:49Z","timestamp":1498328389000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-016-4457-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,13]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["4457"],"URL":"https:\/\/doi.org\/10.1007\/s00059-016-4457-x","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,13]]}}}